丙型肝炎直接抗病毒治疗时代的临床实验室检测
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.
作者信息
Wilson Eleanor M, Rosenthal Elana S, Kattakuzhy Sarah, Tang Lydia, Kottilil Shyam
机构信息
Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Critical Care Medicine Department of the NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Clin Microbiol Rev. 2017 Jan;30(1):23-42. doi: 10.1128/CMR.00037-16. Epub 2016 Oct 19.
Abstract
Directly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.
摘要
用于慢性丙型肝炎病毒（HCV）感染的直接作用抗病毒（DAA）联合疗法非常有效，但治疗决策仍然复杂。在考虑HCV治疗时，实验室检测对于评估一系列病毒、宿主和药理学因素很重要，并且在治疗期间和治疗后必须对患者进行监测，以确保安全并评估病毒反应。在本综述中，我们将根据病毒和宿主因素对DAA治疗时代与HCV感染治疗相关的实验室检测进行讨论。
相似文献
1
Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.丙型肝炎直接抗病毒治疗时代的临床实验室检测
Clin Microbiol Rev. 2017 Jan;30(1):23-42. doi: 10.1128/CMR.00037-16. Epub 2016 Oct 19.
2
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?丙型肝炎病毒感染的数学建模：在直接作用抗病毒药物时代它能教会我们什么？
Antivir Ther. 2012;17(6 Pt B):1171-82. doi: 10.3851/IMP2428. Epub 2012 Oct 5.
3
Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?直接作用抗病毒药物治疗慢性丙型肝炎的未来：耐药性重要吗？
Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x.
4
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.直接作用抗病毒药物治疗慢性丙型肝炎：优势与挑战。
Int J Med Sci. 2020 Mar 15;17(7):892-902. doi: 10.7150/ijms.43079. eCollection 2020.
5
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.丙型肝炎病毒感染中对直接抗病毒药物耐药性在临床实践中的重要性。
J Hepatol. 2016 Feb;64(2):486-504. doi: 10.1016/j.jhep.2015.09.011. Epub 2015 Sep 26.
6
Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports.索磷布韦联合利巴韦林治疗丙型肝炎病毒感染患者的意外应答谱：五例病例报告。
Viral Immunol. 2018 Jul/Aug;31(6):480-483. doi: 10.1089/vim.2017.0199. Epub 2018 Apr 25.
7
Antiviral resistance and direct-acting antiviral agents for HCV.丙型肝炎病毒的抗病毒耐药性与直接作用抗病毒药物
Antivir Ther. 2012;17(6 Pt B):1147-62. doi: 10.3851/IMP2426. Epub 2012 Oct 5.
8
Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure.应对丙型肝炎病毒耐药性和治疗失败的挑战。
Viruses. 2016 Aug 16;8(8):226. doi: 10.3390/v8080226.
9
Highly active anti-hepatitis C therapy: seven lessons from HIV.高效抗丙型肝炎治疗：来自艾滋病治疗的七点经验教训。
Antivir Ther. 2012;17(6 Pt B):1183-8. doi: 10.3851/IMP2429. Epub 2012 Oct 5.
10
Antiviral resistance and specifically targeted therapy for HCV (STAT-C).丙型肝炎病毒的抗病毒耐药性及特异性靶向治疗（STAT-C）
J Viral Hepat. 2009 Jun;16(6):377-87. doi: 10.1111/j.1365-2893.2009.01124.x.
引用本文的文献
1
Comprehensive evaluation of the mechanism of human adipose mesenchymal stem cells ameliorating liver fibrosis by transcriptomics and metabolomics analysis.基于转录组学和代谢组学分析的人脂肪间充质干细胞改善肝纤维化机制的综合评价。
Sci Rep. 2024 Aug 28;14(1):20035. doi: 10.1038/s41598-024-70281-1.
2
HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul.伊斯坦布尔慢性丙型肝炎患者的丙型肝炎病毒基因型分布
Sisli Etfal Hastan Tıp Bul. 2021 Mar 17;55(1):86-92. doi: 10.14744/SEMB.2020.66990. eCollection 2021.
3
VirGenA: a reference-based assembler for variable viral genomes.VirGenA：一种基于参考的可变病毒基因组组装器。
Brief Bioinform. 2019 Jan 18;20(1):15-25. doi: 10.1093/bib/bbx079.
4
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.索磷布韦/维帕他韦：一种泛基因型药物，简化 HCV 治疗。
Hepatol Int. 2017 Mar;11(2):161-170. doi: 10.1007/s12072-016-9776-8. Epub 2016 Dec 7.
本文引用的文献
1
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.对维帕他韦（GS-5816）的临床耐药性，一种新型的丙型肝炎病毒NS5A蛋白泛基因型抑制剂
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5368-78. doi: 10.1128/AAC.00763-16. Print 2016 Sep.
2
Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis.干扰素λ4多态性可预测丙型肝炎病毒患者的持续病毒学应答，不受丙型肝炎病毒基因型、种族或治疗方案影响：一项荟萃分析的结果
Hepat Mon. 2015 Dec 19;15(12):e32707. doi: 10.5812/hepatmon.32707. eCollection 2015 Dec.
3
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.直接作用抗病毒治疗成人丙型肝炎病毒感染：乙型肝炎病毒合并感染的再激活是一个进一步的挑战。
J Clin Virol. 2016 May;78:27-30. doi: 10.1016/j.jcv.2016.02.026. Epub 2016 Mar 3.
4
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.丙型肝炎病毒（HCV）NS3/4A蛋白酶抑制剂格卡瑞韦与HCV NS5A抑制剂艾尔巴韦联合使用，对HCV 1a型复制子的耐药性具有较高的遗传屏障。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May.
5
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.索磷布韦和索磷维伏用于HIV/HCV合并感染患者。
Expert Opin Pharmacother. 2016;17(5):743-9. doi: 10.1517/14656566.2016.1157580. Epub 2016 Mar 16.
6
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.丙型肝炎病毒NS5A抑制剂雷迪帕韦的体外抗病毒活性及耐药谱特征分析
Antimicrob Agents Chemother. 2016 Jan 11;60(3):1847-1853. doi: 10.1128/AAC.02524-15.
7
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.索磷布韦维帕他韦治疗 5 型丙型肝炎病毒感染患者：一项开放标签、多中心、单臂、2 期研究。
Lancet Infect Dis. 2016 Apr;16(4):459-64. doi: 10.1016/S1473-3099(15)00529-0. Epub 2016 Jan 21.
8
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.西米普明联合索磷布韦（12周和8周疗程）用于无肝硬化的丙型肝炎病毒1型感染患者：OPTIMIST-1，一项3期随机研究。
Hepatology. 2016 Aug;64(2):370-80. doi: 10.1002/hep.28467. Epub 2016 Mar 22.
9
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.针对丙型肝炎病毒1型感染的非肝硬化患者的四周直接抗病毒治疗方案：一项开放标签、非随机试验。
Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24.
10
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.索磷布韦维帕他韦片治疗失代偿期肝硬化的丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.
Zotero 插件